阿尔茨海默病治疗的进展:最新综述

Brain-X Pub Date : 2024-07-15 DOI:10.1002/brx2.68
Can Mei, Jianbo Zhan, Shuzhen Zhu, Yutong Zhang, Chang-e Xiong, Jia Wang, Yu Jia Xu, Hua Zhong, Jing Cheng
{"title":"阿尔茨海默病治疗的进展:最新综述","authors":"Can Mei,&nbsp;Jianbo Zhan,&nbsp;Shuzhen Zhu,&nbsp;Yutong Zhang,&nbsp;Chang-e Xiong,&nbsp;Jia Wang,&nbsp;Yu Jia Xu,&nbsp;Hua Zhong,&nbsp;Jing Cheng","doi":"10.1002/brx2.68","DOIUrl":null,"url":null,"abstract":"<p>Alzheimer's disease (AD) is a type of dementia characterized by a decline in brain function, which leads to the inability to perform activities independently. Many researchers recognize abnormalities related to beta-amyloid as the main cause of the disease (i.e., the beta-amyloid hypothesis), but aging, genetics, coronary heart disease, environmental factors, gender, and other risk factors may also contribute to AD development. Three drugs with different mechanisms are available for AD treatment: cholinesterase inhibitors, N-methyl d-aspartate, and aducanumab. This study reviewed the therapies that are already applied in clinical practice and those that are currently being investigated for clinical use. These therapies include not only pharmacological treatments but also non-pharmacological treatments, such as gut flora therapy and music therapy. A comprehensive understanding of these therapies is necessary to enable early intervention, improve patients' physical and mental conditions, delay the occurrence and development of AD, and extend patients' healthy lifespans.</p>","PeriodicalId":94303,"journal":{"name":"Brain-X","volume":"2 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/brx2.68","citationCount":"0","resultStr":"{\"title\":\"Advances of therapy for Alzheimer's disease: An updated review\",\"authors\":\"Can Mei,&nbsp;Jianbo Zhan,&nbsp;Shuzhen Zhu,&nbsp;Yutong Zhang,&nbsp;Chang-e Xiong,&nbsp;Jia Wang,&nbsp;Yu Jia Xu,&nbsp;Hua Zhong,&nbsp;Jing Cheng\",\"doi\":\"10.1002/brx2.68\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Alzheimer's disease (AD) is a type of dementia characterized by a decline in brain function, which leads to the inability to perform activities independently. Many researchers recognize abnormalities related to beta-amyloid as the main cause of the disease (i.e., the beta-amyloid hypothesis), but aging, genetics, coronary heart disease, environmental factors, gender, and other risk factors may also contribute to AD development. Three drugs with different mechanisms are available for AD treatment: cholinesterase inhibitors, N-methyl d-aspartate, and aducanumab. This study reviewed the therapies that are already applied in clinical practice and those that are currently being investigated for clinical use. These therapies include not only pharmacological treatments but also non-pharmacological treatments, such as gut flora therapy and music therapy. A comprehensive understanding of these therapies is necessary to enable early intervention, improve patients' physical and mental conditions, delay the occurrence and development of AD, and extend patients' healthy lifespans.</p>\",\"PeriodicalId\":94303,\"journal\":{\"name\":\"Brain-X\",\"volume\":\"2 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/brx2.68\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain-X\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/brx2.68\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain-X","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/brx2.68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

阿尔茨海默病(AD)是一种以大脑功能衰退为特征的痴呆症,会导致患者无法独立完成活动。许多研究人员认为,与β-淀粉样蛋白有关的异常是该病的主要病因(即β-淀粉样蛋白假说),但衰老、遗传、冠心病、环境因素、性别和其他风险因素也可能导致阿尔茨海默病的发生。目前有三种不同机制的药物可用于治疗AD:胆碱酯酶抑制剂、N-甲基 d-天冬氨酸和阿杜卡单抗。本研究回顾了已应用于临床实践的疗法和目前正在研究用于临床的疗法。这些疗法不仅包括药物疗法,还包括非药物疗法,如肠道菌群疗法和音乐疗法。有必要全面了解这些疗法,以便及早干预,改善患者的身体和精神状况,延缓注意力缺失症的发生和发展,延长患者的健康寿命。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Advances of therapy for Alzheimer's disease: An updated review

Alzheimer's disease (AD) is a type of dementia characterized by a decline in brain function, which leads to the inability to perform activities independently. Many researchers recognize abnormalities related to beta-amyloid as the main cause of the disease (i.e., the beta-amyloid hypothesis), but aging, genetics, coronary heart disease, environmental factors, gender, and other risk factors may also contribute to AD development. Three drugs with different mechanisms are available for AD treatment: cholinesterase inhibitors, N-methyl d-aspartate, and aducanumab. This study reviewed the therapies that are already applied in clinical practice and those that are currently being investigated for clinical use. These therapies include not only pharmacological treatments but also non-pharmacological treatments, such as gut flora therapy and music therapy. A comprehensive understanding of these therapies is necessary to enable early intervention, improve patients' physical and mental conditions, delay the occurrence and development of AD, and extend patients' healthy lifespans.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Issue Information Research progress and applications of optoelectronic synaptic devices based on 2D materials Mechanosensitive Piezo channels and their potential roles in peripheral auditory perception Brain perfusion alterations in patients and survivors of COVID-19 infection using arterial spin labeling: A systematic review Microbiome-gut-brain axis as a novel hotspot in depression
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1